Pelthos Therapeutics Inc.PTHS

$29.00+1.99 (+7.37%)

AMEXHealthcare24:00 UTC

Company snapshot

Market Cap

$96M

Micro-cap

+1100%

2025 — today

10-Year Price

+122%

2025 — today

52-Week Range

$11.70$37.42

Current $29.00· 67%

Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.

Valuation in context

P/E ratio

-0.7

N/A

Not meaningful — company is unprofitable

P/B ratio

2.7

Near historic high

Near historic highs — last 10 years

FCF Yield

-36.8%

Around average

Around the 10-year average

Free · No credit card needed

Get alerted when PTHS is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.